Cancer IVD Market, by Product Type (Reagents, Instruments, Software and Services), by TECHNIQUE (Blood Testing, Tissue Diagnostics), by CANCER TYPE (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Other Cancer Types) and, by END USER (Standalone Laboratory, Hospitals, Academic and Medical Schools, Other End User): Global Opportunity Analysis and Industry Forecast, 2023-2032

• Reagents
• Instruments
• Software and Services

• Blood Testing
• Tissue Diagnostics

• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Prostate Cancer
• Other Cancer Types

• Standalone Laboratory
• Hospitals
• Academic and Medical Schools
• Other End User

• North America  (U.S., Canada, Mexico)
• Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
• Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
• LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)

GlaxoSmithKline, Thermo Fisher Scientific Inc., Olympus Corporation, Qiagen NV, Illumina, Inc., Hologic, Inc., Roche Diagnostics, Abbott Laboratories, Agilent Technologies, Siemens Healthineers